Hepatitis B Therapeutics in Major Developed Markets to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth

Mar 03, 2016, 10:10 ET from Research and Markets

DUBLIN, March 3, 2016 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/2fvhzq/hepatitis_b) has announced the addition of the "Hepatitis B Therapeutics in Major Developed Markets to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth"  report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Over the 2014-2021 forecast period, the hepatitis B market in the eight major markets is expected to increase in value at a CAGR of 2.3% from $2.9 billion to $3.5 billion

Hepatitis B is an infectious liver disease caused by the Hepatitis B Virus (HBV) and characterized by acute or chronic inflammation of the liver. Despite its status as a vaccine-preventable disease, it remains a serious global health concern. Incidence tends to be higher in countries with a significant number of migrants from medium and high-prevalence countries. 

Approximately 350 million people worldwide are infected with chronic hepatitis B, which causes significant morbidity and mortality. Around 780,000 patients die from hepatitis B each year, of which 650,000 deaths are due to complications such as cirrhosis and liver cancer. Despite this, diagnosis and treatment rates are poor, stemming from its asymptomatic nature. 

Key Topics Covered: 

1 Tables & Figures 

2 Introduction 
2.1 Disease Introduction 
2.2 Epidemiology 
2.3 Etiology and Pathophysiology 
2.4 Symptoms 
2.5 Diagnosis 
2.6 Prognosis 
2.7 Treatment and Management 
2.8 Co-infection 

3 Marketed Products 
3.1 Viread 
3.2 Entecavir 
3.3 Pegasys (peg interferon a-2a) 
3.4 Adefovir dipivoxil 
3.5 Tyzeka/Sebivo 
3.6 Comparative Efficacy and Safety 

4 Pipeline Analysis 
4.1 Overview 
4.2 Pipeline Analysis of Therapeutic Vaccines 
4.3 Clinical Trials 
4.4 Competitive Clinical Trials Metrics Analysis 
4.5 Promising Drug Candidates in Pipeline 
4.6 Therapeutic Vaccines in Pipeline 

5 Market Forecast to 2021 
5.1 Geographical Markets 
5.2 Global Market 
5.3 North America 
5.4 Top Five EU Markets 
5.5 Japan 
5.6 Drivers and Barriers in the Disease Market 

6 Deals and Strategic Consolidations 
6.1 Licensing Deals 
6.2 Co-development Deals 

7 Appendix 
7.1 All Pipeline Drugs by Phase of Development 
7.2 Market Forecasts to 2021 
7.3 Bibliography 

Companies Mentioned 

- Artes Biotech 
- Baruch S. Blumberg 
- Bio Farma 
- Chiva 
- Cytos Biotech 
- Dynavax 
- Ligand 
- Merck 
- NeuroVive 
- OnCore 

For more information visit http://www.researchandmarkets.com/research/2fvhzq/hepatitis_b

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Media Contact: 
Laura Wood    
Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470


For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets